퀀텀 바이오파마(QNTM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.80 (+17.65%), 시가총액 $0.05B, 52주 범위 $2.10 ~ $35.00.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation
퀀텀 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
퀀텀 바이오파마의 현재 주가는 $3.80 (+17.65%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
퀀텀 바이오파마의 시가총액은 약 $0.05B입니다.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It r